An analysis of the French IFCT-PREDICT.amm cohort, which consisted of 843 patients with treatment-naive advanced NSCLC, revealed similar rates of METex14 skipping mutations in patients with no or low vs. high MET expression by IHC [62]. The gene discussed is MET; the disease is non-small cell lung carcinoma.